Tiloron-SZ, 125 mg 10 pcs

Low-molecular synthetic inducer of interferon stimulating formation of all types of interferons in the body (alpha, beta, gamma and lambda).

The main producers of interferon in response to tiloron administration are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration the maximum production of interferon is determined in the sequence intestine – liver – blood in 4-24 hours.

Tiloron has immunomodulatory and antiviral effect. After a single oral administration of Tiloron at a dose equivalent to the maximum daily dose for humans, the maximum concentration in the lung tissue of interferon lambda was determined after 24 hours, interferon alpha – after 48 hours.

Induction of interferon lambda in lung tissue increases antiviral protection of the respiratory tract during influenza and other respiratory viral infections.

In human leukocytes it induces interferon synthesis. Stimulates bone marrow stem cells, depending on the dose increases antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers.

Effective against various viral infections including flu viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is connected to inhibition of translation of virus-specific proteins in infected cells, thus suppressing the reproduction of viruses.

Pharmacokinetics

After oral administration it is quickly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug is bound to plasma proteins. The drug is eliminated practically unchanged in intestine (70%) and kidney (9%). The elimination half-life (T1/2) is 48 hours. The drug is not biotransformed and does not accumulate in the body.

Indications

In adults:

– treatment of influenza and other acute respiratory viral infections;

– treatment of herpes infection.

Prevention of influenza and other acute respiratory viral infections in adults.

Pharmacological effect

Pharmacotherapeutic group: antiviral immunostimulating agent – ​​inducer of interferon formation.

ATX code: J05AX

Pharmacological properties

Pharmacodynamics

Low molecular weight synthetic interferon inducer that stimulates the formation of all types of interferons in the body (alpha, beta, gamma and lambda).

The main producers of interferon in response to the administration of tilorone are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence intestines – liver – blood after 4-24 hours.

Tiloron has an immunomodulatory and antiviral effect. After a single oral administration of tilorone at a dose equivalent to the maximum daily dose for humans, the maximum concentration in the lung tissue of interferon lambda was determined after 24 hours, interferon alpha – after 48 hours.

Induction of interferon lambda in lung tissue helps to increase antiviral protection of the respiratory tract during influenza and other respiratory viral infections.

Induces the synthesis of interferon in human leukocytes. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers.

Effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpes viruses. The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which viral reproduction is suppressed.

Pharmacokinetics

After oral administration, it is quickly absorbed from the gastrointestinal tract. Bioavailability – 60%. About 80% of the drug binds to plasma proteins. The drug is excreted almost unchanged through the intestines (70%) and through the kidneys (9%). The half-life (T1/2) is 48 hours. The drug does not undergo biotransformation and does not accumulate in the body.

Special instructions

The influence of a medicinal product for medical use on the ability to drive vehicles and machinery

The drug does not have a negative effect on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Tiloron

Composition

Active substance: tilorone

Pregnancy

The drug is contraindicated during pregnancy. If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.

Contraindications

– Hypersensitivity to tilorone or any other component of the drug;

– pregnancy and breastfeeding period;

– children’s age (up to 18 years).

Side Effects

Possible allergic reactions, dyspepsia, short-term chills.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Compatible with antibiotics and drugs for traditional treatment of viral and bacterial diseases. No clinically significant interaction of tilorone with antibiotics and traditional treatments for viral and bacterial diseases has been identified.

Overdose

Cases of drug overdose are unknown.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

North Star NAO, Russia